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Summary
 
To explore the role of the interleukin (IL)-1
 
b
 
 converting enzyme (ICE) in neuronal apoptosis, we
designed a mutant ICE gene (C285G) that acts as a dominant negative ICE inhibitor. Microin-
jection of the mutant ICE gene into embryonal chicken dorsal root ganglial neurons inhibits trophic
factor withdrawal–induced apoptosis. Transgenic mice expressing the fused mutant ICE-lacZ
gene under the control of the neuron specific enolase promoter appeared neurologically nor-
mal. These mice are deficient in processing pro–IL-1
 
b
 
, indicating that mutant ICE
 
C285G
 
 blocks
ICE function. Dorsal root ganglial neurons isolated from transgenic mice were resistant to
trophic factor withdrawal–induced apoptosis. In addition, the neurons isolated from newborn
ICE knockout mice are similarly resistant to trophic factor withdrawal–induced apoptosis. After
permanent focal ischemia by middle cerebral artery occlusion, the mutant ICE
 
C285G
 
 transgenic
mice show significantly reduced brain injury as well as less behavioral deficits when compared
to the wild-type controls. Since ICE is the only enzyme with IL-1
 
b
 
 convertase activity in
mice, our data indicates that the mutant ICE
 
C285G
 
 inhibits ICE, and hence mature IL-1
 
b
 
 pro-
duction, and through this mechanism, at least in part, inhibits apoptosis. Our data suggest that
genetic manipulation using ICE family dominant negative inhibitors can ameliorate the extent
of ischemia-induced brain injury and preserve neurological function.
 
A
 
poptosis or programmed cell death is a cellular suicide
mechanism under internal cellular control (1, 2). The
genetic control of programmed cell death is best under-
stood in the nematode 
 
Caenorhabditus elegans
 
 (3). Mutations
in the gene 
 
ced-3
 
 eliminate essentially all programmed cell
death that occur during the development of 
 
C. elegans
 
 (4).
Genetic mosaic analysis showed that 
 
ced-3
 
 acts cell autono-
mously to induce cell death and thus, 
 
ced-3
 
 is an essential
component in the cellular suicide mechanism of 
 
C. elegans
 
(5). Members of the IL-1
 
b
 
 converting enzyme (ICE)
 
1
 
 fam-
ily are mammalian homologues of the 
 
C. elegans
 
 
 
ced-3
 
 gene
product (6). Microinjection of crmA, a serpin encoded by
the cowpox virus that is a specific inhibitor of ICE, inhib-
ited neuronal cell death induced by trophic factor depriva-
tion (7). Peptide inhibitors of the ICE family delay motor
neuron death in vitro and in vivo (8). Thus, the ICE pro-
tease family plays an important role in mammalian neuronal
apoptosis.
Traditionally, ischemia-mediated neuronal cell death has
been attributed to necrosis, rather than to apoptosis. This is
based on the morphological feature of dying neurons of post-
ischemic brain that include swelling and disintegration of
cell membrane, rather than typical cellular shrinkage and
nuclear changes seen in apoptosis. Recently, however, the
conventional view that necrosis is the major, if not the
only, mechanism of ischemia-mediated neuronal degenera-
tion has been challenged. Evidence of activation of apop-
 
1
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totic mechanisms in postischemic cerebral tissue of adult
animals has been detected. Internucleosomal cleavage of
DNA has been observed both after global (9, 10) and focal
(11–13) occlusions. These studies suggest that apoptosis
may play an important role in postischemic neuronal cell
death. It is not clear, however, which are the genetic and
biochemical pathways mediating neuronal apoptotic cell
death induced by ischemic insult.
While the critical role of ICE-like proteases in apoptosis
has been well established, the role of ICE itself in apoptosis
remains controversial. ICE knock out mutant mice gener-
ated by gene targeting techniques were found to be only
partially defective in apoptosis induced by anti-Fas anti-
body (14). On the other hand, we and others have found
elevated levels of mature IL-1
 
b
 
 after apoptotic cell death
indicating activation of ICE in apoptosis, since ICE is likely
the only enzyme in vivo and in vitro with IL-1
 
b
 
 conver-
tase activity (14–18). We have previously demonstrated that
binding of endogenously produced mature IL-1
 
b
 
 to its
type 1 receptor plays an important role in apoptosis (19). We
have shown that replacing the cysteine in the active site of
ICE with a glycine (C285G) obliterates its ability to medi-
ate cell death (20). The cysteine residue in the active site is
required for the IL-1
 
b
 
 convertase and the autoprocessing
activity of ICE (21). We demonstrate here that ICE
 
C285G
 
mutant is a dominant negative inhibitor of ICE that can
inhibit processing of pro–IL-1
 
b
 
 by ICE in vivo. Expression
of mutant ICE
 
C285G
 
 in dorsal root ganglial (DRG) neurons,
either by microinjection or in transgenic mice, inhibits
trophic factor withdrawal–induced apoptosis. In addition,
DRG neurons of ICE knockout mice are also resistant to
trophic factor deprivation-induced apoptosis, consistent with
the notion that mutant ICE
 
C285G
 
 inhibits ICE directly. Fi-
nally, we show here that transgenic mice expressing the
ICE
 
C285G
 
 mutant under the control of neuron specific eno-
lase (NSE) promoter are resistant to neuronal injury in-
duced by cerebral ischemia.
 
Materials and Methods
 
Microinjection of 
 
b
 
-Actin-M17Z into Chicken Embryonic DRG
Neurons.
 
The experiments were performed essentially as de-
scribed by Gagliardini et al. (7). Primary cultures of chicken
embryonic DRG neurons were isolated under sterile conditions
from day 10 embryos (Spafas Inc., Preston, CT). DRGs were dis-
sociated by incubation in trypsin for 15 min at 37
 
8
 
C and tritura-
tion. Dissociated neurons were plated on poly-
 
l
 
-lysine– (30 mg/ml
for 1 h; Sigma Chemical Co., St. Louis, MO) and laminin–
(Sigma Chemical Co.; 20 mg/ml for 2 h) coated chamber slides.
DRG neurons were cultured for 2 d in F12 medium (GIBCO BRL,
Gaithersburg, MD) containing 10% fetal bovine serum (Hyclone
Labs., Logan, UT), penicillin (100 U/ml; GIBCO BRL), strepto-
mycin (100 mg/ml; Sigma Chemical Co.), and 5 mM cytosine
 
b
 
-
 
d
 
-arabinose (Sigma Chemical Co.) supplemented with nerve
growth factor (NGF; 10 ng/ml; Sigma Chemical Co.). Neuron
injection was performed with a microinjector (model 5242; Ep-
pendorf Inc., Fremont, CA), with glass micropipettes loaded with
1 mg/ml plasmid DNA in Tris/EDTA buffer and 5% rhodamine
dye (10 kD rhodamine-isothiocyanite–labeled dextran; Molecular
Probes Inc., Eugene, OR), dissolved in 0.2 M KCl. The construc-
tion of the fused mutant ICE (C285G)-lacZ plasmid (
 
b
 
-actin-
M17Z) was described by Miura et al. (20). 3 h after injection, the
NGF-containing medium was replaced with NGF- and serum-
free medium in the presence of sufficient mouse monoclonal an-
tibody against NGF (Boehringer Mannheim, Indianapolis, IN).
The medium was changed daily. Live injected neurons were
counted on days 0, 3, and 6.
 
Construction of NSE-M17Z Plasmid and Generation of Transgenic
Mice.
 
pNSE-M17Z-lacZ construct was made by digesting
pNSE-lacZ with SalI and ClaI, which removed a 0.8-kb SalI/
ClaI fragment. The SalI/ClaI digested pNSE-lacZ vector was li-
gated with a 2-kb SalI/ClaI insert from BSM17Z that contains
the mutant ICE (C285G) and the part of lacZ that was removed
in the SalI/ClaI digest of the pNSE/lacZ vector. The resulting
construct was named pJ655. To generate transgenic mice, pJ655
was linearized by XmnI digestion and gel purified. 14 transgenic
mice lines were generated by DNX (Princeton, NJ). Founder
mice were SV-129/C57BL/6 hybrid. Initially, five lines were se-
lected (7506, 7512, 7516, 7538, and 7539) based on highest
DNA copy number in the genome.
 
Genotyping and X-galactosidase Assay of M17Z Mice.
 
Tail DNA
was isolated and genotyping was performed using the follow-
ing  PCR primers targeted to the 
 
Ice/lacZ
 
 fusion (M17Z-F:
5
 
9
 
TGCCCAAGCTTGAAAGACAAGCCC3
 
9
 
, lacZ-R: 5
 
9
 
CTG-
GCGAAAGGGGGATGTGCTG3
 
9
 
). X-gal staining was per-
formed by removing the vertebral column and sectioning it in a
sagital plane. Tissue was fixed for 5 min on ice (0.2% glutaralde-
hyde in 0.1 M phosphate buffer, 2% formaldehyde, 5 mM EGTA,
pH 7.3, 2 mM MgCl
 
2
 
) followed by three 30 min washes at 4
 
8
 
C
(0.1 M phosphate buffer, pH 7.3, 2 mM MgCl
 
2
 
, 0.1% sodium
deoxycholate, 0.2% NP40). The tissue was then stained overnight
with X-gal at 37
 
8
 
C (rinse solution with 1 mg/ml X-gal in
DMSO, 5 mM K ferrocyanide, 5 mM K ferricyanide), and then
sectioned in a cryostat (40 
 
m
 
m). Photomicrograph was taken in a
light microscope (
 
3
 
100) under oil immersion.
 
Facial Nucleus Neuronal Count.
 
Facial motorneurons were counted
as described by Martinou et al. (22). Briefly, 40 
 
m
 
m brainstem sec-
tions of 6-wk-old mice were stained with cresyl violet. Neurons
were counted double blindly in both facial nuclei. All sections
were counted and no correction was applied.
 
Pro–IL-1
 
b
 
 Processing After Systemic LPS Administration.
 
LPS from
 
Escherichia coli
 
 serotype 0111:B4 was dissolved in 0.1 M PBS (pH
7.4). Each mouse (transgenic 29.5 
 
6 
 
1.2 g, 
 
n
 
 
 
5
 
 11; wild type
29.6 
 
6 
 
2.1 g, 
 
n
 
 
 
5
 
 7) was injected intraperitoneally either with 10
 
m
 
g of LPS/g body weight, or with equivalent volume of PBS at 0
and 12 h, and killed by decapitation under halothane anesthesia 2 h
after the second injection. Brains were rapidly dissected and fro-
zen in 1.5 ml Eppendorf tubes in liquid nitrogen. Brain tissue
concentration of mature IL-1
 
b
 
 was determined in duplicate using
an ELISA kit (Intertest
 
TM
 
-1
 
b
 
X, Lot B6499F; Genzyme Corp.,
Cambridge, MA). Brains without olfactory bulbs and cerebellum
were homogenized in two volumes of ice-cold 0.1 M PBS contain-
ing 2 mM phenylmethylsulfonylfluoride, 1 
 
m
 
g/ml leupeptin, 1 
 
m
 
g/
ml antipain, 1 
 
m
 
g/ml aprotinin, 1 
 
m
 
g/ml pepstatin, 0.05% (wt/
vol) sodium azide and 4 mM ethylenediaminetetraacetic acid us-
ing a microtube homogenizer (Sigma Pellet Pestle; Sigma Chem-
ical Co.) for 15 s. The homogenates were centrifuged for 30 min
at 50,000 
 
g
 
, and 100 
 
m
 
l of the supernatant was used for each deter-
mination. Absorbance was read at 450 nm with an ELISA plate
reader (Multiskan MCC/340 MK II; Titertek, Elfab Oy, Fin-
land). Values shown are as mean 
 
6 
 
SEM.
 
Newborn DRG Neuron Trophic Factor Deprivation.
 
The experi- 
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ments were performed as described by Friedlander et al. (19).
Postnatal day 1 mouse DRG neurons were isolated, dissociated
with trypsin for 1 h at 37
 
8
 
C, and plated in an eight-chamber poly-
 
l
 
-lysine/laminin– (Sigma Chemical Co.) coated slide. Wells were
seeded at a density of 
 
z
 
1,000 neurons/well (eight wells/mouse).
Neurons were cultured in Ham’s F-12 media supplemented with
20% FCS (BioWhittaker, Inc., Walkersville, MD), NGF (200
ng/ml) (Sigma Chemical Co.), brain-derived neurotrophic factor
(100 ng/ml; Preprotech, Rocky Hill, NJ), glutamine (2 mM),
and penicillin/streptomycin. The medium was replaced with ei-
ther trophic factor–containing medium (TF[
 
1
 
] 
 
5
 
 20% FCS and
200 ng/ml NGF) or trophic factor–deficient medium (TF[
 
2
 
] 
 
5
 
serum- and NGF-free medium in the presence of a saturating
concentration of mouse NGF monoclonal antibody (100 ng/ml;
Boehringer Mannheim).
 
Permanent Middle Cerebral Artery Occlusion.
 
Experiments were
done as described by Hara et al. (23), except that the occlusion of
the middle cerebral artery (MCA) was continuous for 24 h. Neu-
rological grading: 0, no neurological deficits; 1, failure to extend
the right forepaw; 2, circling to the contralateral side; 3, loss of
walking or righting reflex. All experiments were done in a dou-
ble-blinded fashion. Values shown as mean 
 
6 
 
SEM.
 
Results
 
Mutant ICE Protects DRG Neurons from Trophic Factor
Withdrawal–induced Apoptosis.
 
Survival of DRG neurons
in culture requires the presence of trophic factors which in-
clude nerve growth factor and serum. In the absence of tro-
phic factor support, DRG neurons undergo apoptosis (24). To
determine whether the mutant ICE can inhibit DRG neu-
ronal death induced by trophic factor deprivation, primary
cultures of chicken embryonic DRG neurons were micro-
injected with a construct of the fused mutant ICE
 
C285G
 
-lacZ
gene under the control of the 
 
b
 
-actin promoter (
 
b
 
-actin-
M17Z). Neurons were co-injected with rhodamine-iso-
thiocyanate dextran as a marker and with Hoechst dye to
determine neuronal nuclear morphology. After trophic fac-
tor removal, control neurons microinjected with the 
 
b
 
-actin-
lacZ construct survived 22.5 and 6.0% after 3 and 6 d in
culture, respectively. No significant difference was detected
when compared to cells injected with dye alone. In con-
trast, neurons injected with 
 
b
 
-actin-M17Z survived 85.0
and 81.0% after 3 and 6 d in culture, respectively (Fig. 1).
These results showed that the mutant ICE gene inhibits
DRG neuronal cell death induced by trophic factor depri-
vation, suggesting that mutant ICE may be able to suppress
the activities of wild-type ICE or ICE-like proteases.
 
Generation of Transgenic Mice Expressing the Mutant ICE
(C285G) Protein.
 
To determine whether the mutant ICE
gene can also act as an inhibitor of apoptosis in vivo, and to
further evaluate its mechanism of action, we established
transgenic mouse lines expressing the fused mutant ICE
 
C285G
 
-
lacZ gene under the control of the NSE promoter (NSE-
M17Z). Transgenic mice expressing either the lacZ or bcl-2
genes under control of the NSE promoter have been well
characterized, and transgene expression has been detected
throughout the nervous system (22, 25, 26). PCR was used
for genotyping the NSE-M17Z transgenic mice, and pro-
tein expression was detected by X-gal staining (Fig. 2).
Founder mice from five different lines were crossed with
C57BL/6 mice. The expression of NSE-M17Z was de-
tected in the first and second generations of offspring,
which were used in the experiments described below.
 
NSE-M17Z Transgenic Mice Are Developmentally Nor-
mal. NSE-M17Z mice are viable and their embryonic
development appears normal. Developmental apoptosis
does not appear to be inhibited in these mutant ICEC285G
transgenic mice, as evidenced by equal brain size, normal
behavior, as well as equal number of neurons in the facial
motor nucleus, when compared to their wild-type litter-
mates (wild type [n 5 6] 2,323 6 77, transgenic [n 5 6]
2,355 6 84). The lack of an embryonic phenotype in the
mutant ICEC285G mice suggests that mutant ICE does not
block neuronal apoptosis during development. Alterna-
tively, since the NSE promoter is active at low levels dur-
ing embryogenesis, the expression of the mutant ICE gene
might not reach a threshold sufficient to block develop-
mental cell death (25).
Mutant ICE Acts In Vivo as a Dominant Negative Inhibitor
of ICE. We next evaluated whether the mutant ICEC285G
may act as a dominant negative ICE inhibitor. ICE knock-
out mice were almost completely defective in processing
pro–IL-1b and ICE is the only protease identified so far
that can process pro–IL-1b (14, 17). If the mutant ICE
transgenic mice have a defect in secreting mature IL-1b,
this would provide strong evidence that mutant ICEC285G
can act as a dominant negative inhibitor of ICE. Systemic
injection of LPS induces release of mature IL-1b, and ICE
knockout mice generated by gene-targeting technique were
unable to release mature IL-1b upon LPS stimulation (14,
17). To determine if our mutant ICEC285G transgenic mice
Figure 1. Microinjection of b-actin-M17Z protects embryonic chicken
DRG neurons from trophic factor withdrawal–induced apoptosis. Survi-
val represents the percentage of injected E10 chick DRG neurons remain-
ing alive at 3 and 6 d (100% at day 0) after trophic factor deprivation. A
total of 783 neurons were injected with vector alone (solid bar), 421 with
dye alone (empty bar), and 850 with b-actin-M17Z (hatched bar). Each
condition was done on at least four independent experiments. Results are
expressed as means 6 SEM.936 Inhibition of Neuronal Apoptosis in a Mouse Expressing an ICE Inhibitor
are also defective in secreting mature IL-1b, we injected
LPS intraperitoneally into the mutant ICEC285G transgenic
mice and determined the levels of mature IL-1b in whole
brain lysates using an ELISA kit which specifically detects
mature IL-1b. After the systemic LPS challenge, whole brain
lysates of mutant ICEC285G transgenic mice contained 74.7%
less mature IL-1b as compared to that of LPS-injected wild-
type mice. In control wild-type mice injected intraperito-
neally with PBS, there was low but detectable levels of
mature IL-1b in the brain (4.0 pg/g brain), whereas this
cytokine was undetectable in the brain lysate of PBS-injected
mutant ICEC285G mice (Fig. 3). Thus, mutant ICEC285G can
act as an effective inhibitor of pro–IL-1b processing, strongly
suggesting that mutant ICEC285G is a dominant negative in-
hibitor of ICE itself.
Newborn DRG Neurons from the Mutant ICEC285G Trans-
genic and ICE Knockout Mice Are Resistant to Trophic Factor
Withdrawal–induced Apoptosis. We have previously dem-
onstrated that a CrmA-sensitive pathway, as well as ICE ac-
tivation followed by endogenously produced mature IL-1b
receptor binding, play important roles in trophic factor
withdrawal–mediated DRG neuron apoptosis (7, 19). In
this same model, we investigated whether DRG neurons
isolated from mutant ICEC285G mice were resistant to cell
death. DRG neurons were isolated from newborn mutant
ICEC285G transgenic and wild-type mice, and cultured in
the presence or absence of trophic factor. The survival of
wild-type and NSE-M17Z mice DRG neurons in the
presence of trophic factor were .95% after 24 h in culture.
Removal of trophic factor induces 79.7% of neurons to die
Figure 2. (a) X-gal staining of a DRG from transgenic 6-wk-old mouse progeny of the 7539 founder (prog-
eny of the 7512 founder had similar staining pattern). (b) PCR genotyping of transgenic lines. M17Z is the ori-
ginal NSE-M17Z plasmid which was used to make the transgenic mouse, used here as a PCR positive control.
7512 and 7539 are positive transgenic lines.937 Freidlander et al.
within 24 h. DRG neurons from two transgenic lines (7512
and 7539) were significantly protected from apoptosis in
culture (48.6% cell death in 24 h) after trophic factor re-
moval as compared to their wild-type littermates (Fig. 4 a).
If resistance of DRG neurons isolated from mutant ICEC285G
mice to trophic factor deprivation–induced apoptosis can
be attributed to the ability of mutant ICE to inhibit endog-
enous ICE activity, a prediction would be that DRG neu-
rons from ICE knockout mice should also be resistant to
neuronal cell death induced by trophic factor deprivation.
To test this hypothesis, we examined whether DRG neu-
rons from ICE knockout mice are also protected from
trophic factor withdrawal–mediated apoptosis. Newborn
DRG neurons were isolated from mutant ICE knockout and
control wild-type mice. As shown in Fig. 4 b, DRG neu-
rons isolated from ICE knockout mice are similarly resistant to
cell death induced by trophic factor deprivation as our mu-
tant ICEC285G transgenic mice. These results suggest that
mutant ICEC285G acts as a dominant negative inhibitor of ICE
for the suppression of DRG neuronal cell death–induced
apoptosis and that ICE plays an important role in DRG
neuronal cell death induced by trophic factor deprivation.
NSE-M17Z Transgenic Mice Are Resistant to Cerebral Is-
chemic Injury. To determine if ICE plays a role in apopto-
sis induced by ischemic insult and if the mutant ICEC285G
may act to reduce ischemic brain injury, we investigated
whether the mutant ICEC285G transgenic mice were pro-
tected in a mouse focal cerebral ischemia model where apop-
totic cell death has been reported (27). We performed per-
manent MCA occlusion in 14 wild-type and 11 transgenic
mice, progeny of five different founder mice (7509, 7512,
7516, 7538, and 7539). Mice were scored neurologically
30 min and 24 h after the occlusion. In the initial 30 min
evaluation, there was no significant difference in the neuro-
logical score. During the ensuing 24 h, however, wild-type
mice remained impaired, while transgenic mice improved
neurologically (Fig. 5 A). Mice were killed at 24 h, and in-
farct volume was quantified with 4% 2,3,5-triphenyltetra-
zolium chloride. Infarct volume was significantly smaller in
NSE-M17Z (66 6 11 mm3 [n 5 11]) when compared to
the wild-type littermate mice (125 6 5 mm3 [n 5 14]; Fig. 5
B). Physiologic parameters were recorded in a separate set
of transgenic and wild-type mice. Blood pressure, arterial
Figure 3. Whole brain lysates of NSE-M17Z mice are deficient in pro-
cessing pro–IL-1b after systemic LPS administration. LPS was injected in-
traperitoneally (10 mg/g body weight) and 2 h before killing (wild type,
n 5 4; NSE-M17Z, n 5 5). PBS was injected as a control (wild type, n 5 3;
NSE-M17Z, n 5 6). Brains were dissected, and mature IL-1b concentra-
tion was determined using an ELISA kit specific for mature IL-1b. Re-
sults are expressed as means 6 SEM.
Figure 4. Survival in vitro of NGF-dependent DRG neurons isolated
from (a) mutant ICEC285G transgenic and (b) ICE knockout newborn mice
are protected from trophic factor withdrawal–mediated apoptosis. Sur-
vival represents the percentage of neurons remaining alive after 24 h of
serum deprivation (100% at day 0). (a) The results are the average three
double blindly scored independent experiments using newborn mice
from lines 7512 and 7539. Neurons from each mouse were plated sepa-
rately, and at least 400 neurons were counted per well. Results are ex-
pressed as means 6 SEM. (b) Results are from an experiment double
blindly scored performed in quadruplicate, from DRG neurons isolated
from four wild-type and four ICE knockout newborn mice. At least 500
neurons were counted per well. Results are expressed as means 6 SD.938 Inhibition of Neuronal Apoptosis in a Mouse Expressing an ICE Inhibitor
blood gases (PO2, PCO2, and blood pH), regional cerebral
blood flow, and body temperature did not significantly differ
in the two sets of mice, before and throughout 30 min of is-
chemia (Fig. 5 C). Thus, expression of mutant ICEC285G, a
dominant negative inhibitor of ICE, protects neurons from
ischemic insult.
Discussion
We show here that the mutant ICEC285G inhibits apoptosis
in two different species (chicken and mouse) and under the
control of two different promoters (b-actin and NSE). We
presented convincing evidence that mutant ICEC285G acts as
a dominant negative inhibitor of ICE by inhibiting process-
ing of pro–IL-1b. X-ray crystallography analysis showed
that ICE exists as a dimer of two p20 and two p10 subunits
processed from two p45 precursor molecules (28). Expres-
sion of a catalytically inactive mutant of ICE may result in
formation of inactive dimers which will inhibit endogenous
wild-type ICE function. Since DRG neurons from ICE
knockout mice were protected from trophic factor depriva-
tion–induced apoptosis as were DRG neurons from NSE-
M17Z transgenic mice, we believe that, at least in DRG
neurons, the mutant ICEC285G prevented neuronal cell death
by inhibiting ICE activity. This is consistent with our pre-
vious data that demonstrate that the addition of the IL-1
receptor antagonist, a naturally existing IL-1b antagonist,
inhibited mouse DRG neuronal cell death induced by
trophic factor deprivation, suggesting that release of mature
IL-1b processed by ICE plays an active role in apoptosis
induced by trophic factor deprivation (19).
We determined the role of ICE-like proteases in apopto-
sis induced by cerebral ischemia in a mouse permanent fo-
cal stroke model. We found that NSE-M17Z transgenic
mice suffered less tissue injury and less behavioral changes
as a result of ischemic injury, compared to the wild-type
mice. Although we cannot rule out the possibility that the
reduction of neuronal damage by mutant ICE is due to its
ability to inhibit other members of the ICE family, evi-
dence suggests that ICE itself plays an important role in ce-
rebral ischemia-induced cell death. Elevated levels of IL-1b
are detected after cerebral ischemia (29). In addition, intra-
ventricular administration of the IL-1 receptor antagonist
decreases infarct size after permanent MCA occlusion (30).
We have also demonstrated that endogenously produced
mature IL-1b plays an important role in hypoxia-mediated
apoptosis in vitro (19). These results suggest the involve-
ment of ICE and of mature IL-1b receptor binding in the
mechanism of ischemia-induced cell death. Our results fur-
ther corroborate the notion that ICE plays an important
role in apoptosis induced by ischemic injury. After expo-
sure to certain death stimuli, the ICE cell death cascade is
activated. As demonstrated here, and in previous studies,
apoptosis may be inhibited by blocking the ICE cell death
cascade, either the activation of pro-ICE, the function of
active ICE, or the product of ICE activity which is mature
IL-1b (7, 19, 31). We cannot rule out, however, that mu-
tant ICEC285G may also cross-inhibit other cell death gene
Figure 5. Protection from permanent MCA occlusion–mediated infarct
in NSE-M17Z (black) compared to wild-type (white) mice. (A) Neurolog-
ical grading 30 min and 24 h after occlusion. Neurological grading: 0, no
neurological deficits; 1, failure to extend the right forepaw; 2, circling to
the contralateral side; 3, loss of walking or righting reflex. (B) Infarct area
assessed at 24 h. (C) Regional cerebral blood flow (rCBF), and mean arte-
rial blood pressure (MBP) of wild-type and transgenic mice during 30 min
of ischemia (**, P ,0.01).939 Freidlander et al.
products, since subunits of different ICE family members
sharing significant sequence homology may bind to each
other forming heterooligomeres (21). Due to the limited
availability of the ICE knockout mice to us, we were unable
to examine directly if the ICE knockout mice are resistant
to ischemic injury. Since embryonic development of the mu-
tant ICEC285G and of ICE knockout mice are normal and
no significant defect in embryonic apoptosis was uncovered
(14, 17), a nonredundant function of ICE in developmental
apoptosis has been ruled out. We demonstrated here that
transgenic mice expressing a dominant negative mutant ICE
are significantly protected from neuronal cell death induced
by ischemic insult, suggesting that ICE may play an impor-
tant role in pathological cell death. Our results suggest that
ischemic-induced injury, and possibly other disorders fea-
turing apoptosis, can be treated with inhibitors aimed at
modulating the activity of the ICE protease family to re-
duce tissue injury and preserve brain function.
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